TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12627305

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWIG, n=9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Double-cold-water immersion (DCWIG, n=9)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (COTG, n=10)
Number of subjects: 28
Study: 11052843

Group type: EXPERIMENTAL
Intervention: Elective stent placement (7‐cell NIR stent)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Optimal balloon angioplasty
Number of subjects: 120
Study: 8826310

Group type: EXPERIMENTAL
Intervention: Automated medication distribution systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-benefit analysis
Number of subjects: 0
Study: 1425647

Group type: EXPERIMENTAL
Intervention: 20 min at 60% VO2max
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 min at 60% VO2max
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 min at 70% VO2max
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 min at 70% VO2max
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All sessions
Number of subjects: 8
Study: 3931802

Group type: EXPERIMENTAL
Intervention: Yoga exercises including breathing exercises, suryanamaskar, yogasana, pranayama, dhyana, and a devotional session practiced for 65 minutes daily.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual drugs (control group).
Number of subjects: 53
Study: 29300977

Group type: EXPERIMENTAL
Intervention: Salk polio vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27609809

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccines (low or medium dose of hemagglutinin with AS03A or AS03B)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccines
Number of subjects: 420
Study: 24768811

Group type: EXPERIMENTAL
Intervention: Exercise training (n=9), 3 days/week for 8 weeks at 60%-80% of baseline peak VO2
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Exercise training (n=9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care (controls, n=10)
Number of subjects: 19
Study: 22234380

Group type: EXPERIMENTAL
Intervention: Exercise (10-min moderate-intensity stationary cycling)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive control (seating for the same duration)
Number of subjects: 20
Study: 21291034

Group type: EXPERIMENTAL
Intervention: 6 mg/day 17beta‐estradiol (E2) orally with progesterone vaginal gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Progesterone vaginal gel without 6 mg/day 17beta‐estradiol (E2)
Number of subjects: 60
Study: 18344178

Group type: EXPERIMENTAL
Intervention: Antioxidant tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study: 15779884

Group type: EXPERIMENTAL
Intervention: Pre-exposure to target nameless objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pre-exposure to objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-exposure to non-target members of nameless object categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-exposure to a nameless object
Number of subjects: 0

Group type: COMPARATOR
Intervention: Familiar object or unfamiliar object not pre-exposed
Number of subjects: 0
Study: 12053635

Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 100 mg/d)
Number of subjects: 87

Group type: COMPARATOR
Intervention: St John's wort (900 to 1800 mg/d)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 87

Group type: COMPARATOR
Intervention: St John's wort
Number of subjects: 87
Study: 11895822

Group type: EXPERIMENTAL
Intervention: Use of Informed Choice leaflets in intervention units
Number of subjects: 6432

Group type: COMPARATOR
Intervention: Usual care in control units
Number of subjects: 6432
Study: 9541155

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 7542268

Group type: EXPERIMENTAL
Intervention: RT-PCR assay
Number of subjects: 94
Study: 2364508

Group type: EXPERIMENTAL
Intervention: Nitrendipine (1,4‐dihydro‐2,6‐dimethyl‐4‐[m‐nitrophenyl]‐3,5‐pyridine‐dicarboxylic acid ethyl methylester)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 40
Study: 534318

Group type: EXPERIMENTAL
Intervention: Fasting for 7-10 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet for 9 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal diet (Control)
Number of subjects: 26
Study: 6354607

Group type: EXPERIMENTAL
Intervention: 150 mg proglumetacin twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: 250 mg naproxen twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proglumetacin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 30156201

Group type: EXPERIMENTAL
Intervention: Single-stage closure (Push back palatoplasty)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (children without CLP)
Number of subjects: 55
Study: 26040978

Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin (OT)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 20 IU intranasal vasopressin (AVP)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 25041312

Group type: EXPERIMENTAL
Intervention: Fitzpatrick Skin Type Scale - Sun Exposure subscale
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Fitzpatrick Skin Type Scale - Genetic Disposition subscale
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Fitzpatrick Skin Type Scale - Tanning Habits subscale
Number of subjects: 244
Study: 22297104

Group type: EXPERIMENTAL
Intervention: Active PRFE device
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 70
Study: 20593944

Group type: EXPERIMENTAL
Intervention: Community-based educational messages on cervical cancer and its prevention (intervention group)
Number of subjects: 350

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 350
Study: 17306565

Group type: EXPERIMENTAL
Intervention: High predictability of action effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low predictability of action effect
Number of subjects: 0
Study: 15975182

Group type: EXPERIMENTAL
Intervention: Infant products (commercially available fortified infant cereals/ready-to-eat canned baby foods/formula milk powder)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Infant cereals
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Ready-to-eat canned baby foods
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Complementary diet
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Animal products
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Dairy products
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Vitamin-A-rich fruit and vegetables
Number of subjects: 475
Study: 14728544

Group type: EXPERIMENTAL
Intervention: Back safety training intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient transfer training intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10643685

Group type: COMPARATOR
Intervention: Low-intensity exercise (30% of VO2max for 60 min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (60% of VO2max for 30 min)
Number of subjects: 32
Study: 8656259

Group type: EXPERIMENTAL
Intervention: Etoposide 2 micrograms/mL
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Etoposide 3 micrograms/mL
Number of subjects: 49
Study: 1497928

Group type: EXPERIMENTAL
Intervention: Cervical mediastinoscopy
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Anterior mediastinotomy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Both procedures (anterior mediastinotomy and cervical mediastinoscopy)
Number of subjects: 95
Study: 6694336

Group type: EXPERIMENTAL
Intervention: Track-and-field athletics training for 9 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 21
Study: 30715758

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin membrane (test group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Inorganic bovine bone substitute and a resorbable collagen barrier membrane (control group)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Incisor and canine region (subgroup)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Premolar region (subgroup)
Number of subjects: 27
Study: 30620868

Group type: EXPERIMENTAL
Intervention: 0.96% zinc (zinc oxide, zinc citrate), 1.5% L‐arginine and 1450 ppm fluoride as sodium fluoride in a silica base, Test 1
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.96% zinc (zinc oxide, zinc citrate), 1.5% L‐arginine and 1000 ppm fluoride as sodium fluoride in a silica base, Test 2
Number of subjects: 180

Group type: COMPARATOR
Intervention: 1450 ppm fluoride as sodium fluoride in a silica base, Control
Number of subjects: 180
Study: 27264058

Group type: EXPERIMENTAL
Intervention: 800 IU cholecalciferol daily
Number of subjects: 474

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study: 23931093

Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 156

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 156
Study: 21975293

Group type: EXPERIMENTAL
Intervention: ANH (acute normovolemic hemodilution)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 93
Study: 20152212

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 20
Study: 18831983

Group type: EXPERIMENTAL
Intervention: Younger subjects; performance improved when elements were aligned along the contour path.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older subjects; performance not affected by the orientation of local elements.
Number of subjects: 0
Study: 16007473

Group type: EXPERIMENTAL
Intervention: Probing at T0 (immediate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Probing at T1 (1 hour)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Probing at T4 (4 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Probing at T24 (24 hours)
Number of subjects: 20
Study: 12638326

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEI)
Number of subjects: 41
Study: 10226901

Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 68

Group type: COMPARATOR
Intervention: Prostacyclin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 68
Study: 8669998

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined electrical stimulation and biofeedback
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 45
Study: 1725911

Group type: EXPERIMENTAL
Intervention: High-dose verapamil treatment (Isoptin RR 240 mg twice daily)
Number of subjects: 196

Group type: COMPARATOR
Intervention: 10 mg of nifedipine four times daily
Number of subjects: 196

Group type: COMPARATOR
Intervention: 90 mg of diltiazem three times daily
Number of subjects: 196
Study: 7042502

Group type: EXPERIMENTAL
Intervention: Dimepropion-HCI
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study: 29489608

Group type: EXPERIMENTAL
Intervention: Displayed checklist
Number of subjects: 131

Group type: COMPARATOR
Intervention: Handheld checklist
Number of subjects: 131

Group type: COMPARATOR
Intervention: No checklist
Number of subjects: 131
Study: 26994212

Group type: EXPERIMENTAL
Intervention: M-quantile regression model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26422640

Group type: EXPERIMENTAL
Intervention: Individualized lifestyle referral assessment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual assessment
Number of subjects: 132
Study: 23897015

Group type: EXPERIMENTAL
Intervention: Cooling (phase change cooling vest)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (shorts and T-shirt)
Number of subjects: 10
Study: 24075050

Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 1080
Study: 20693587

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg per kg of body weight)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 19041042

Group type: EXPERIMENTAL
Intervention: Continuous radiofrequency (CRF) thermocoagulation at 80 degrees C for 75 seconds
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF) at 42 degrees C with a pulse duration of 20 ms and pulse rate of two Hz for 120 seconds
Number of subjects: 50
Study: 16172571

Group type: EXPERIMENTAL
Intervention: FDG PET with a median SUVmax of 2.6 in cases with complete remission (CR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FDG PET with a median SUVmax of 3.4 for tumors that did not relapse
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tumors with higher SUVmax
Number of subjects: 40
Study: 14556918

Group type: EXPERIMENTAL
Intervention: Various chemotherapy regimens for advanced NSCLC
Number of subjects: 42661

Group type: EXPERIMENTAL
Intervention: Larger studies
Number of subjects: 42661

Group type: EXPERIMENTAL
Intervention: More recent studies
Number of subjects: 42661

Group type: EXPERIMENTAL
Intervention: Trials from countries with only one published eligible study
Number of subjects: 42661

Group type: EXPERIMENTAL
Intervention: Platinum and/or taxane and combination regimens
Number of subjects: 42661

Group type: EXPERIMENTAL
Intervention: Performance status of patients
Number of subjects: 42661
Study: 10589641

Group type: EXPERIMENTAL
Intervention: Fentanyl (10 microg in 200 microL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microg in 200 microL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine (1000 microg in 200 microL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine (100 microg in 200 microL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (200 microL)
Number of subjects: 12
Study: 8697854

Group type: EXPERIMENTAL
Intervention: Percutaneous dilational tracheostomy (PDT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Surgical tracheostomy (ST)
Number of subjects: 53
Study: 1726209

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil suspension (3 and 6 mg/kg)
Number of subjects: 476
Study: 6753114

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirenzepine (75 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31876200

Group type: EXPERIMENTAL
Intervention: MTX + CsA (7.5 mg MTX and 2.5 mg/kg CsA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTX + Placebo (7.5 mg MTX and placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MTX + CsA
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTX + Placebo
Number of subjects: 40
Study: 31778618

Group type: EXPERIMENTAL
Intervention: Hemochromatosis cases
Number of subjects: 37092
Study: 29872859

Group type: EXPERIMENTAL
Intervention: Lower SpO2 target range (85%-89%)
Number of subjects: 4965

Group type: COMPARATOR
Intervention: Higher SpO2 target range (91%-95%)
Number of subjects: 4965
Study: 25782170

Group type: EXPERIMENTAL
Intervention: 10 mg ambroxol (AXS)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: 5 mg ambroxol (AXS)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: 2.5 mg ambroxol (AXS)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study: 24056366

Group type: EXPERIMENTAL
Intervention: Toothguide Trainer (TT) and Toothguide Training Box (TTB) training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 78
Study: 21324570

Group type: EXPERIMENTAL
Intervention: Quercetin 4x500 mg orally within 24 hours
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19470041

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid photodynamic therapy (ALA-PDT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5% imiquimod cream (IMIQ)
Number of subjects: 30
Study: 17481859

Group type: EXPERIMENTAL
Intervention: Rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) at a dosage of 0.1 mg/kg
Number of subjects: 3
Study: 15047131

Group type: EXPERIMENTAL
Intervention: 4 mg/kg rhIGF‐I/IGFBP‐3 for one‐week intervals
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal children (comparison group)
Number of subjects: 10
Study: 11673081

Group type: COMPARATOR
Intervention: Centenarian males
Number of subjects: 54

Group type: COMPARATOR
Intervention: Younger control men
Number of subjects: 54

Group type: COMPARATOR
Intervention: Centenarian females
Number of subjects: 54

Group type: COMPARATOR
Intervention: Young women
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 54
Study: 9551246

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (100 mg/kg on the first day followed by 75 mg/kg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Cefotaxime (200 mg/kg/day in four divided doses)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 82
Study: 7624192

Group type: EXPERIMENTAL
Intervention: Heterogeneous condition
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Homogeneous condition
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 10
Study: 2677126

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 100
Study: 233545

Group type: EXPERIMENTAL
Intervention: Oral metaproterenol administered daily for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 0
Study: 31303295

Group type: EXPERIMENTAL
Intervention: Facility birth
Number of subjects: 119244

Group type: EXPERIMENTAL
Intervention: Facility birth in areas closer to CEmOC facilities
Number of subjects: 119244

Group type: EXPERIMENTAL
Intervention: Increasing wealth
Number of subjects: 119244

Group type: EXPERIMENTAL
Intervention: Increasing distance from childbirth facilities
Number of subjects: 119244
Study: 25851102

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 3232

Group type: COMPARATOR
Intervention: Metformin or placebo
Number of subjects: 3232

Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 3232
Study: 24034963

Group type: EXPERIMENTAL
Intervention: Peer oriented behavioral intervention including six small group peer educator-training sessions and three booster sessions plus HIV testing and counseling (HTC)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Peer oriented behavioral intervention
Number of subjects: 419

Group type: COMPARATOR
Intervention: Control group receiving only HIV testing and counseling (HTC)
Number of subjects: 419
Study: 21991942

Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator lung function
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Post-bronchodilator lung function
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator lung function (Stage 3 or 4 disease)
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Post-bronchodilator lung function (Stage 3 or 4 disease)
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator lung function (Year 5 sample)
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Post-bronchodilator lung function (Year 5 sample)
Number of subjects: 5887
Study: 18975305

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 356
Study: 16867142

Group type: EXPERIMENTAL
Intervention: Treatment effects analysis using fecal terminal restriction fragment length polymorphism data sets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Principle components analysis and cluster analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large within-subject sample size and multiple baseline samples
Number of subjects: 0
Study: 12622345

Group type: EXPERIMENTAL
Intervention: Cellular phone monitoring (CM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paper-and-pencil self-monitoring (PM)
Number of subjects: 20
Study: 10683797

Group type: EXPERIMENTAL
Intervention: Healon5
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Healon5 and Viscoat
Number of subjects: 35
Study: 8821083

Group type: EXPERIMENTAL
Intervention: Patients with hippocampal sclerosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with frontal lobe lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 9511639

Group type: EXPERIMENTAL
Intervention: Amalgaphase
Number of subjects: 82

Group type: COMPARATOR
Intervention: Dispersalloy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Amalga 43
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Permite C
Number of subjects: 82
Study: 6468034

Group type: EXPERIMENTAL
Intervention: 3 X 1500 mg Cefuroxim (Zinazef) for three days, starting 1 h prior to the operation
Number of subjects: 61

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 61
Study: 30452914

Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging (AFI)
Number of subjects: 802

Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 802
Study: 30265153

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for 1 year followed by placebo for 1 year
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil for 2 years
Number of subjects: 142

Group type: COMPARATOR
Intervention: Pooled groups (Cyclophosphamide and Mycophenolate)
Number of subjects: 142